STRATEC SE

Earnings Release • May 14, 2003

News Details

Ad-hoc | 14 May 2003 08:45

Stratec Biomedical Sys. english

STRATEC maintains its clear growth trajectory Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– STRATEC maintains its clear growth trajectory Birkenfeld, May 14, 2003 The Board of Management of STRATEC Biomedical Systems AG, listed in the German Prime Standard, hereby issues a precautionary announcement of the results for the first quarter of 2003, ending on March 31, 2003, pursuant to Section 15 of the German Securities Trading Law (WpHG). The overall performance and sales saw clear two-figure growth. Sales rose by 39.9% to EUR 5.124m (2002: EUR 3.663m). The overall performance improved by 22.5% to EUR 5.562m (2002: EUR 4.539m). Reference is made by the company to the fact that the first quarter of a given fiscal year was traditionally its weakest quarter. STRATEC increased its net income for the period to EUR 0.056m (2002: EUR 0.023m). This results in undiluted earnings per share (EPS) amounting to EUR 0.02 (2002: EUR 0.01). These calculations are based on around 3.3 million shares. Overview of Key Figures pursuant to IAS/IFRS: Key Figures in EUR 000s 1st Quarter 2003 1st Quarter 2002 Change Sales 5,124 3,663 + 39.9% Overall performance 5,562 4,539 + 22.5% EBITDA 354 288 + 22.9% EBIT 156 93 + 67.7% EBT 98 42 + 133.3% Net income for the period 56 23 + 143.5% end of ad-hoc-announcement (c)DGAP 14.05.2003 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: As has already been emphasized, in terms of sales and earnings at STRATEC Biomedical Systems AG, the first quarter has always been the weakest in the fiscal year. The weak first quarter of 2002, for example, produced only 14% of the sales for the overall fiscal year. Milestone invoicing for development activities and income from license agreements have an even more marked effect on earnings than on sales or the overall performance. The first quarter of 2002 produced only around 3% of the earnings contributions for the overall year. STRATEC achieved earnings per share (EPS) pursuant to IAS/IFRS of 34 cents in the 2002 fiscal year. About STRATEC Biomedical Systems AG: STRATEC ( http://www.stratec-biomedical.de ) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems together with their own reagents to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. STRATEC is a publicly listed stock corporation. Shares in the company (WKN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and on other exchanges. At the end of the first quarter, STRATEC had 142 employees (2002: 122). The more extensive interim report can be downloaded from our homepage from around 3 p.m. on May 14, 2003. Further information can be obtained from: STRATEC Biomedical Systems AG Investor Relations André Loy Gewerbestraße 37 75217 Birkenfeld Tel: +49 (0) 70 82 / 79 16 43 Fax: +49 (0) 70 82 / 79 16 999 eMail: ir@stratec-biomedical.de ——————————————————————————– WKN: 728900; ISIN: DE0007289001; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard) und Stuttgart; Freiverkehr in Berlin-Bremen, Düsseldorf und München 140845 Mai 03